Chordate Medical Holding AB (publ)

OM:CMH PREF Stock Report

Market Cap: SEK 5.8m

Chordate Medical Holding Management

Management criteria checks 3/4

Chordate Medical Holding's CEO is Anders Weilandt, appointed in Jun 2017, has a tenure of 7.75 years. directly owns 4.49% of the company’s shares, worth SEK258.69K. The average tenure of the management team and the board of directors is 8.3 years and 7.9 years respectively.

Key information

Anders Weilandt

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure7.8yrs
CEO ownership4.5%
Management average tenure8.3yrs
Board average tenure7.9yrs

Recent management updates

No updates

Recent updates

No updates


CEO

Anders Weilandt (63 yo)

7.8yrs

Tenure

Mr. Anders Weilandt served as Director at Neola Medical AB (formerly known as GPX Medical AB (publ)) since May 2022 until 2024. Mr. Weilandt serves as the Chief Executive Officer at Chordate Medical Holdin...


Leadership Team

NamePositionTenureCompensationOwnership
Anders Weilandt
CEO & MD7.8yrsno data4.49%
SEK 258.7k
Niklas Lindecrantz
Chief Financial Officer7.4yrsno data0.036%
SEK 2.1k
Jan Lindberg
CTO and Head of R&D13.2yrsno data0.010%
SEK 582.1
Jan Hermansson
Chief Scientific Officer and Clinical Research & Medical Directorno datano data0.31%
SEK 17.6k
Helena Thedius
Sales & Marketing Manager8.8yrsno datano data

8.3yrs

Average Tenure

63yo

Average Age

Experienced Management: CMH PREF's management team is seasoned and experienced (8.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Tommy Hedberg
Independent Director10.8yrsSEK 100.00k5.24%
SEK 302.2k
Gunilla Lundmark
Independent Director7.9yrsSEK 100.00kno data
Henrik Rammer
Independent Chairman10.3yrsSEK 180.00k1.36%
SEK 78.4k
Caroline Brandberg
Independent Director3.4yrsSEK 100.00k5.96%
SEK 343.5k
Otto Skolling
Vice Chairman1.8yrsSEK 140.00kno data

7.9yrs

Average Tenure

61yo

Average Age

Experienced Board: CMH PREF's board of directors are considered experienced (7.9 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/25 15:53
End of Day Share Price 2025/03/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chordate Medical Holding AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.